Ricky Yang

Ricky Yang serves as the Chief Financial Officer at 215 Capital, where he plays a pivotal role in guiding the firm's financial strategies across its diverse investment portfolio, with a particular emphasis on the biotechnology and pharmaceutical sectors.

With over a decade of experience in financial management within the biotech industry, Mr. Yang has a proven track record of overseeing finance portfolios for companies generating revenues in excess of $500 million. His expertise spans the implementation of robust financial controls and the execution of strategic growth initiatives, which have consistently driven substantial value for the organizations he has worked with.

At 215 Capital, Mr. Yang leads the firm's financial planning, capital allocation, and investor relations efforts. He is instrumental in evaluating potential investments and optimizing the financial performance of portfolio companies, ensuring that they achieve their strategic objectives and maximize returns for stakeholders.

Mr. Yang holds an MBA from the NYU Stern School of Business and a Bachelor of Science in Accounting and Finance from the Lehigh University College of Business. He is also a Certified Public Accountant, accredited by the New York State Education Department.